← All indications
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Subtype terms (9)
More specific conditions that are subtypes of Ovarian Neoplasms in the MeSH hierarchy.
- Brenner Tumor
22 drugs (16 approved, 6 experimental)
- Carcinoma, Endometrioid
21 drugs (15 approved, 6 experimental)
- Carcinoma, Ovarian Epithelial
172 drugs (65 approved, 107 experimental)
- Granulosa Cell Tumor
2 drugs approved
- Hereditary Breast and Ovarian Cancer Syndrome
10 drugs (6 approved, 4 experimental)
- Luteoma
- Meigs Syndrome
- Sertoli-Leydig Cell Tumor
1 drug approved
- Thecoma
Drugs by status
Approved for this indication (21)
- chlorambucil
- trabectedin
- olaparib
- 4-hydroxycyclophosphamide
- doxorubicin
- rucaparib
- melphalan
- niraparib
- multi-epitope folate receptor alpha-loaded dendritic cell vaccine
- mirvetuximab soravtansine
- cisplatin
- gemcitabine
- satumomab pendetide
- altretamine
- paclitaxel
- defactinib
- avutometinib
- topotecan
- amifostine
- thiotepa
- carboplatin
Phase 4 trials (24)
Phase 3 trials (125)
- atorvastatin
- fosbretabulin
- diphenhydramine
- gl-onc1
- oregovomab
- exemestane
- epothilone
- vinblastine
- glutathione
- capecitabine
- Ofranergene obadenovec
- modafinil
- Chiauranib
- prednisolone
- ql1706
- docetaxel
- gen-1
- ifosfamide
- saracatinib
- thalidomide
- axitinib
- cytarabine
- folic acid
- cyclophosphamide
- decitabine
- acetylcarnitine
- karenitecin
- mitoxantrone
- ly4170156
- shr-a1912
- +95 more
Phase 2 trials (585)
- berzosertib
- ipilimumab
- ashwagandha extract
- dpx-survivac
- urokinase-derived peptide a6
- trop2-car-nk
- montanide isa 720
- yangzhengxiaoji
- art0380
- tazemetostat
- so-c101
- allopurinol
- tigatuzumab
- glufosfamide
- elu001
- lenalidomide
- larotrectinib
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- 2x-121
- auranofin
- alvocidib
- nilotinib
- tumour infiltrating lymphocytes
- gi-102
- enb003
- u3-1402
- elenagen
- or502
- olaratumab
- oncos-102
- +555 more
Phase 1 trials (369)
- tsc-200-a0201
- mrx0518
- tbi-1301
- ltt462
- pidilizumab
- [111in]-fpi-1547
- moma-313
- kb-0742
- dm002
- colloidal gold-bound tumor necrosis factor
- abexinostat
- miransertib
- globo-h-gm2-stn-tf-tn-klh conjugate
- azafol
- ad5-delta24rgd
- mage-12 peptide vaccine
- tnhyp217 car t cells
- ro6870810
- imab027
- perflutren protein-type a microspheres
- mm-310
- ec1456
- bbi-355
- km1
- u3-1565
- brivanib alaninate
- 211-astatine mx35 f(ab')2
- alvac-cea-b7.1 vaccine
- muc1-klh vaccine/qs21
- sgn-tgt
- +339 more
Other trials (39)
- granisetron
- nedaplatin
- ficlatuzumab
- lutropin alpha
- wheat
- motexafin lutetium
- nkg2d car-nk
- hydrocortisone
- her-2 icd peptide
- 3,3',5,5'-tetraiodothyroacetic acid
- [18f]f-resca-t4
- avm0703
- 111in-j591
- polyvalent vaccine-klh conjugate
- frd001
- mk-0646
- [68ga]ga-nota-t4
- remifentanil
- in111 folic acid
- essiac
- autologous blood
- (s)-4-(3-fluoropropyl)-l-glutamic acid
- huaier
- desflurane
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- ga-nota-rt4
- lithium
- technetium tc 99m sulesomab
- bvd-523
- inactivated influenza vaccine
- +9 more
Organizations
Organization Involved with Phase 4 Indications (15)
- Zhejiang University
- University of Chicago
- University of Milan
- Harvard University
- ARCAGY-GINECO
- Mario Negri Institute
- Shandong University
- Fondazione Giovanni Pascale
- University of Campania Luigi Vanvitelli
- Kalmar Central Hospital
- Merck
- Duke University
- Linkoping University
- Maastricht University
- Centre François Baclesse
Organization Involved with Phase 3 Indications (152)
- MEI Pharma
- Fudan University
- Gynecologic Oncology Trial & Investigation Consortium
- National Health and Medical Research Council, Australia
- European Network for Gynaecological Oncological Trial Groups
- Facing Our Risk of Cancer Empowered
- Cochrane Cancer Network
- Federation of Italian Cooperative Oncology Groups
- Impact Therapeutics, Inc.
- Zai Lab Pty. Ltd.
- European Network for Gynaecological Oncological Trial
- Apices Soluciones S.L.
- Canadian Cancer Trials Group
- Theradex
- University of Glasgow
- Guangzhou Medical University
- Mateon Therapeutics
- Hopital Arnaud de Villeneuve
- Swiss Group for Clinical Cancer Research
- Boryung Pharmaceutical Company
- Gynecological Oncology Center South (GOCZ)
- Chongqing Cancer Institute
- Chinese Academy of Medical Sciences
- Sequus Pharmaceuticals
- Korean Gynecologic Oncology Group
- Unither Pharmaceuticals
- University of Copenhagen
- Hengrui Therapeutics, Inc.
- European Organisation for Research and Treatment of Cancer
- Universidad Complutense de Madrid
- +122 more
Organization Involved with Phase 2 Indications (372)
- KuDOS
- Celgene
- NewVac LLC
- Department of Radiation Oncology
- National Cancer Institute, France
- Astellas
- University of Connecticut
- OSI Pharmaceuticals
- University of Texas at Houston
- Jinan University
- Chipscreen Biosciences, Ltd.
- University of California, San Diego
- Ångstrom Pharmaceuticals
- Burzynski Research Institute
- University of Michigan
- Essex Pharma
- University of Texas, San Antonio
- Qingfeng Pharmaceutical Group
- University of Melbourne
- Leap Therapeutics, Inc.
- Seattle Genetics
- The University of Texas, Dallas
- Georgetown University
- University of Electronic Science and Technology of China
- Charles University
- Rutgers University
- PharmaBio Development Inc.
- Syndax Pharmaceuticals
- Synteract, Inc.
- Japan Clinical Oncology Group
- +342 more
Organization Involved with Phase 1 Indications (79)
- Oncolix, Inc.
- Oncology Institute of Southern Switzerland
- ImmunoVaccine Technologies, Inc.
- Placon Therapeutics
- Southern Illinois University
- Novella Clinical
- Oregon Health and Science University
- Transgene
- Virginia Commonwealth University
- Mereo BioPharma
- IRCCS CANDIOLO
- Department of Defense
- Ganymed Pharmaceuticals AG
- Hrain Biotechnology Co., Ltd.
- National Hospital Organisation Shikoku Cancer Centre
- Xencor
- Kyowa Hakko Kirin
- Stemcentrx
- Loma Linda University
- Biomarin
- Genelux
- Swedish Cancer Society
- Pharmacyclics
- Sutro Biopharma
- Northwell Health
- Cascadian Therapeutics Inc.
- Agensys, Inc.
- Asana BioSciences
- Vastra Gotaland Region
- Intrexon
- +49 more
Organization Involved with Other Experimental Indications (7)